December 13, 2011
Intarcia and Quintiles Finalize Innovative Alliance to Advance Global Phase 3 Program for ITCA 650 in Type 2 Diabetes

October 21, 2011
Intarcia and Quintiles Sign Letter of Intent for Innovative Global Collaboration to Advance ITCA 650 in Type 2 Diabetes

September 14, 2011
Intarcia Presents Positive 48-week Results from Phase 2 Study of ITCA 650 at the 47th Annual Meeting of European Association for the Study of Diabetes

June 28, 2011
Intarcia Presents Positive Phase 2 48-week Results from ITCA 650 Study at the American Diabetes Association 71st Scientific Sessions

September 22, 2010
Intarcia Presents Positive ITCA 650 Phase 2 Study Results for Type 2 Diabetes at EASD

September 16, 2010
Intarcia Therapeutics Names Kurt Graves Executive Chairman to Advance Strategic Interests and Broaden Commercial Goals

June 28, 2010
Intarcia Therapeutics, Inc. Presents Positive ITCA 650 Phase 2 Study Results as a Late-Breaker at the American Diabetes Association 70th Scientific Sessions

November 06, 2009
Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting

September 30, 2009
Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference

September 17, 2009
Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes

June 8, 2009
Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions

May 27, 2009
Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-breaker Presentation at the American Diabetes Association 69th Scientific Sessions

April 24, 2009
Intarcia Therapeutics, Inc. Completes Enrollment of Phase 1b Clinical Trial of ITCA 650 (DUROS delivery of exenatide) In Patients With Type 2 Diabetes

September 09, 2008
Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research

June 6, 2007
FierceBiotech Names Intarcia Therapeutics as One of the "Fierce 15" Biotech Companies of 2007

May 21, 2007
Intarcia Therapeutics Announces Presentation of Final Results from a Phase 2 Combination Study for the Treatment of Hepatitis C at the Digestive Disease Week Conference

April 12, 2007
Intarcia Therapeutics Announces Final Results From A Phase 2 Study Of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatitis C Genotype-1

March 19, 2007
Intarcia Raises $50 Million in a Series BB Financing